179 related articles for article (PubMed ID: 20065058)
21. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
23. [In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M; Kanda M; Tsujio Y; Kimoto H; Kaimori M; Nakamura T; Kawamura C; Nishimura M; Akizawa K; Katayama Y; Matsuda K; Hayashi T; Yasujima M; Kasai T; Kimura M; Tominaga M; Miki M; Nakanowatari S; Nakagawa T; Kaku M; Kanemitsu K; Kunishima H; Toyoshima S; Sakurai M; Shiotani J; Sugita A; Ito T; Okada J; Suwabe A; Yamahata K; Yoneyama A; Kumasaka K; Yamane N; Koike K; Ieiri T; Kominami H; Yamada T; Oguri T; Itoh K; Watanabe K; Kobayashi Y; Ohtake T; Uchida T; Totsuka K; Murakami M; Yomoda S; Takahashi A; Okamoto H; Inuzuka K; Yamazaki K; Gonda H; Yamashita T; Yamaguchi I; Okada M; Ikari H; Kurosawa N; Fujimoto Y; Ishigo S; Asano Y; Mikio M; Kano I; Nagano E; Kageyama F; Shaku E; Kanno H; Aihara M; Gemma H; Uemura K; Miyajima E; Maesaki S; Hashikita G; Horii T; Sumitomo M; Yoshimura H; Hiraoka M; Wada H; Yuzuki Y; Ikeda N; Baba H; Soma M; Yamamoto T; Ichiyama S; Kinosita S; Kawano S; Fujita S; Kageoka T; Hongo T; Okabe H; Tatewaki K; Moro K; Oka M; Niki Y; Yoshida H; Yamashita M; Kusano N; Mihara E; Nose M; Fushiwaki T; Kuwabara M; Fujiue Y; Shimuzu A; Takubo T; Kusakabe T; Hinoda Y; Tanaka N; Takahashi H; Heijyou H; Okazaki T; Asai K; Kawahara K; Masuda J; Sano R; Taminato T; Negayama K; Matsuo S; Komatsu M; Sugiura T; Murase M; Hiramatsu K; Yamane N; Nakasone I; Hirakata Y; Kohno S; Aizawa H; Honda J; Hamazaki N; Okayama A; Ono J; Aoki Y; Okada K; Miyanohara H
Jpn J Antibiot; 2006 Dec; 59(6):428-51. PubMed ID: 17334061
[TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Wenzler S; Schmidt-Eisenlohr E; Daschner F
Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
26. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
[TBL] [Abstract][Full Text] [Related]
27. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
[TBL] [Abstract][Full Text] [Related]
28. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
Decousser JW; Allouch PY; Courvalin P; Leclercq R;
Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
31. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
35. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
Lai CC; Liu WL; Ko WC; Chen YH; Tan HR; Huang YT; Hsueh PR
Antimicrob Agents Chemother; 2011 May; 55(5):2084-91. PubMed ID: 21343461
[TBL] [Abstract][Full Text] [Related]
36. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Johnson AP; Warner M; Livermore DM
Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
[TBL] [Abstract][Full Text] [Related]
37. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.
Miranda AG; Wanger AR; Singh KV; Murray BE
Antimicrob Agents Chemother; 1992 Jun; 36(6):1325-8. PubMed ID: 1329621
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
